Assessment of effect of multifocal contact lenses on myopia progression rates in children and adolescents

Brien Holden Vision Institute0 个研究点目标入组 20 人开始时间: 2011年11月1日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•have successfully participated in study IERP2007-009
•-be able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent (or their parent(s)/legal guardian);
•-if under 18 years of age, be accompanied by their parent(s)/legal guardian when signing the informed consent form;
•-be willing to comply with the wearing and clinical trial visit schedule as directed by the investigator;
•-have ocular health findings considered to be normal” and which would not prevent the participant from safely wearing contact lenses;
•-have vision correctable to at least 6/9 (20/30) or better in each eye with contact lenses;

•-pre-existing ocular irritation that would preclude contact lens fitting;
•-an ocular condition that may preclude safe wearing of contact lenses;
•-an active corneal infection or any active ocular disease that would affect wearing of contact lenses;
•-a need for concurrent category S3 and above ocular medication up to 12 weeks prior to and during the trial;
•-any systemic disease that may affect ocular health. Conditions such as systemic hypertension do not automatically exclude prospective participants;
•-any systemic or topical medications up to 12 weeks prior to and during the trial that will affect ocular physiology or the performance of the lenses;
•-had eye surgery within 12 weeks immediately prior to enrolment for this trial;
•-undergone corneal refractive surgery;
•-any ocular injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids that would affect the wearing of contact lenses;
•-contraindications to contact lens wear;
•-had orthokeratology
•-binocular vision problems such as strabismus or amblyopia
•-any participant from anti myopia studies who has any unresolved ocular problem
•-currently enrolled in another clinical trial

发起方

Brien Holden Vision Institute